Why Site And Partner Communications Are Critical To Autologous Cell Therapy Clinical Trials

By Karen Ivester, inSeption Group

Autologous cell therapy expertise and service providers are simultaneously in short supply and high demand. But the dynamic nature of inherently complex cell therapy-focused clinical trials requires individuals with a keen understanding of site and partner needs. Moreover, to fully take advantage of these individuals’ capabilities, responsive, high-touch coordination and a plan to communicate effectively across multiple stakeholders are necessary.

Such communication is critical to deliver the cross-functional, integrated clinical development activities necessary to decrease development time and to prevent and/or mitigate a myriad of risks. While clear, consistent communications are important to any clinical trial, the consequences of mistakes are exacerbated in autologous cell therapy clinical trials.

Plus, building a rapport with proficient sites is more difficult, since personnel with cell and gene therapy experience are highly sought-after and prone to moving around between organizations and projects.